Clinical characteristics and treatment outcomes of natural killer/T-cell lymphoma involving the ocular adnexa.
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cohort Studies
Disease-Free Survival
Female
Humans
Killer Cells, Natural
/ pathology
Lymphoma, T-Cell
/ drug therapy
Male
Maxillary Sinus Neoplasms
/ drug therapy
Middle Aged
Mouth Neoplasms
/ drug therapy
Nose Neoplasms
/ drug therapy
Orbital Neoplasms
/ drug therapy
Retrospective Studies
Survival Rate
Treatment Outcome
Young Adult
masquerading syndrome
natural killer T-cell lymphoma
ocular adnexal lymphoma
survival analysis
Journal
The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
03
01
2018
revised:
08
03
2018
accepted:
12
03
2018
pubmed:
1
5
2018
medline:
21
9
2019
entrez:
1
5
2018
Statut:
ppublish
Résumé
To evaluate the clinical characteristics and treatment outcomes of natural killer/T-cell lymphoma (NKTL) involving the ocular adnexa. Retrospective, comparative, observational case series. A total of 350 patients with NKTL, including 27 patients with NKTL involving the ocular adnexa from 1999 to 2016. The patients were grouped into two groups: group 1 comprised patients presenting with ophthalmic symptoms, and group 2 comprised patients presenting with symptoms from other organs but subsequently developed ophthalmic involvement. Group 1 comprised 12 patients (44.4%) and group 2 comprised 15 (55.6%). Mean duration of symptoms in group 1 was 1.8±1.2 months, while the time from diagnosis of NKTL to development of ophthalmic symptoms in group 2 was 45.3±65.6 months. Periorbital swelling was the most common presenting symptom in both groups (83.3% in group 1 and 73.3% in group 2). Symptoms mimicking cellulitis and pseudotumor were present in 50.0% and 16.7% of cases, respectively. The 5-year overall survival rate was 18.5% in group 1 and 26.4% in group 2, while the 5-year progression-free survival rate was 0% and 13.3%, respectively. Our series is to our knowledge the largest cohort study on NKTL reported to date and demonstrates that ocular adnexal NKTL is a rare but seriously fatal disease. It is characterised by acute inflammatory signs as present in as many as two-thirds of our patients in this series. It should be considered as a differential diagnosis in patients presenting with rapidly progressing proptosis and diagnosed promptly for optimal management.
Identifiants
pubmed: 29706604
pii: bjophthalmol-2017-311704
doi: 10.1136/bjophthalmol-2017-311704
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
269-273Informations de copyright
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.